NCT01113762

Brief Summary

Younger hip patients often need revision of their hip replacement due to wear and loosening. Newer concepts (resurfacing and large head total hip replacement) with articulation surfaces in metal may reduce the wear, increase the longevity of the implant and give an improved function. The possible downside is that these concepts releases metal debris to the body. The investigators wish to see if the newer interventions are a clinical improvement compared to standard. The investigators also wish to investigate the extent of metal released to the body and any effect on the immune system. Finally the investigators wish to investigate the stability of these new implants and their ability to preserve the bone around the implant. The investigators hypothesis is: That the metal on metal articulations will not have better clinical outcomes than standard The resurfacing implant is expected to preserve the bone of the upper femoral bone. The implants are expected to be stabile within the first year.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
71

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Feb 2007

Longer than P75 for phase_2

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 30, 2010

Completed
9.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
Last Updated

December 19, 2017

Status Verified

December 1, 2017

Enrollment Period

2.8 years

First QC Date

April 28, 2010

Last Update Submit

December 17, 2017

Conditions

Keywords

Arthroplasty, Replacement, HipBone DensityRehabilitationT-LymphocytesChromium Alloys

Outcome Measures

Primary Outcomes (5)

  • Range of motion

    range of motion in the hip joint evaluated by goniometer

    Up to two months before surgery

  • Range of motion

    Range of motion of the hip joint

    8 weeks +/- 1 week

  • Range of motion

    range of motion in the hip joint

    6 months +/- 2 weeks

  • Range of motion

    range of motion in the hip joint

    1 year +/- 1 month

  • range of motion

    range of motion in the hip joint

    2 year +/- 1 month

Secondary Outcomes (53)

  • Metal ions

    Up to two months before surgery

  • BMD

    Within the first week following surgery

  • RSA

    Within the first week following surgery

  • HHS

    Up to two months before surgery

  • UCLA activity

    Up to two months before surgery

  • +48 more secondary outcomes

Study Arms (4)

resurfacing

EXPERIMENTAL

a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint

Device: articular surface replacement ASR, DePuy

large head THA

EXPERIMENTAL

a standard stemmed THA but with a large metal head, and a metal-metal articulation

Device: ReCap/Magnum modular head, Biomet

28 mm ceramics-polyethylene

ACTIVE COMPARATOR

a standard 28 mm head uncemented THA

Device: Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet

28 mm metal-polyethylene THA

ACTIVE COMPARATOR

a standard stemmed uncemented THA

Device: 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)

Interventions

posterolateral incision

resurfacing

posterolateral incision

large head THA

posterolateral incision

28 mm ceramics-polyethylene

posterolateral incision

28 mm metal-polyethylene THA

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary hip osteoarthritis
  • Secondary osteoarthritis due to mild dysplasia
  • Age from 40 to 65 years

You may not qualify if:

  • Dysplasia with CE angle \< 25 degrees on the AP projection
  • Severe femoral head deformation
  • Reduced femoral neck length
  • Leg length discrepancy more than 1 cm
  • Need for restoration of offset
  • Deformation after fractures or earlier osteotomies
  • A previous hip arthroplasty
  • Inflammatory arthritis
  • Endocrinological disease with bone metabolic manifestations
  • Renal disease
  • Malignant disease
  • Neuro/muscular or vascular diseases of the affected leg
  • Osteoporosis
  • Use of opioid pain killers due to other diseases
  • High dose corticosteroids
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Naestved Hospital Dept. of orthop. surg.

Næstved, 4700, Denmark

Location

Odense University hospital

Odense, 5000, Denmark

Location

Related Publications (3)

  • Penny JO, Varmarken JE, Ovesen O, Nielsen C, Overgaard S. Metal ion levels and lymphocyte counts: ASR hip resurfacing prosthesis vs. standard THA: 2-year results from a randomized study. Acta Orthop. 2013 Apr;84(2):130-7. doi: 10.3109/17453674.2013.784657.

  • Penny JO, Ovesen O, Varmarken JE, Overgaard S. Similar range of motion and function after resurfacing large-head or standard total hip arthroplasty. Acta Orthop. 2013 Jun;84(3):246-53. doi: 10.3109/17453674.2013.788435. Epub 2013 Mar 26.

  • Nissen T, Douw K, Overgaard S. Patient-reported outcome of hip resurfacing arthroplasty and standard total hip replacement after short-term follow-up. Dan Med Bull. 2011 Oct;58(10):A4310.

MeSH Terms

Conditions

Osteoarthritis, Hip

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Soeren Overgaard, MD, professor, phd

    University of Southern Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

April 28, 2010

First Posted

April 30, 2010

Study Start

February 1, 2007

Primary Completion

November 1, 2009

Study Completion

November 1, 2019

Last Updated

December 19, 2017

Record last verified: 2017-12

Locations